SEATTLE -- A new study adds support to an increasing body of evidence that the common childhood bacterial infection known informally as strep throat is associated with an increased risk for some neurologic conditions that frequently start in childhood -- Tourette's syndrome (TS), Obsessive-compulsive disorder (OCD) and tic disorder.
The study, conducted at the Group Health Center for Health Studies (CHS) in Seattle, was published in the July 5, 2005 edition of the journal Pediatrics. It suggests that
strep throat (streptococcal infection) doubles the risk for a first diagnosis of TS, OCD or tic disorder within three months after infection. Multiple infections appear to approximately triple the risk for a first diagnosis of these disorders within 12 months.
"There are likely a number of different causes for these conditions, which
often show up first in childhood or adolescence," explained Robert L. Davis,
MD, MPH, senior researcher at CHS and the study's corresponding author.
"Following a number of different leads from past research, we've found more
tantalizing clues about possible connections between childhood infections and
certain disorders. However, our findings certainly don't suggest that there is
any immediate need for a change in medical -- or parental -- practice."
Davis did not suggest that parents and physicians should be more worried.
Nor did he suggest parents do anything differently if their child gets strep
throat. "Right now, this is all still in the research stage," said Davis. "We
still don't know if treatment with common antibiotics helps prevent these
neurologic conditions that might follow strep throat, or reduce their
severity, or shorten their duration if they do occur."
These disorders are more common than previously appreciated. OCD affects
1 percent to 2 percent of school-age children, and transient tics can affect up to 10 percent to 25 percent of elementary school-age children. Some researchers suspect the body's natural response to infection -- the production of certain antibodies directed to
parts of the brain -- might be linked in some way to pediatric autoimmune
neuropsychiatric disorders (PANDAS), including TS, OCD, and tic disorder.
"Although the presence of these antibodies is more frequent among children
with tics or TS, there's much we still don't know," said Davis. "For example,
why do millions of children get strep throat every year, but only a tiny
fraction develop these disorders?"
Davis and other researchers think that a person's genes may play a
critical role. One theory is that the strep infection might serve as a trigger
for symptoms in only those children who carry a particular gene or set of
genes. "It's a promising avenue for additional study," Davis said.
The study examined the medical records of 202 pediatric patients with TS,
OCD or tic disorder at Group Health, occurring between 1992 and 1999. Children
were more than twice as likely as a control group (who did not have the
disorders) to have had at least one streptococcal infection in the three
months before disease onset, and almost twice as likely to have had a least
one streptococcal infection in the 12 months before onset. Incidence of the
disorders was more than three times as common among patients who'd had two or
more step infections in the year before onset.
Other study authors include Loren K. Mell, MD of the Pritsker School of
Medicine, University of Chicago, and David Owens, MD, of the University of
Washington School of Medicine.
Group Health is a consumer-governed, nonprofit health care system that
coordinates care and coverage. Based in Seattle, Group Health and Group Health
Options, Inc. serve nearly 550,000 members in Washington and Idaho. Group
Health's Center for Health Studies conducts research related to prevention,
diagnosis, and treatment of major health problems. The Center for Health
Studies is funded primarily through government and private research grants.
Source: Group Health Cooperative
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.